Metlife (MET) Earnings Dates, Call Summary & Reports

Compare

2,946 Followers

Earnings Data

Report Date

May 06, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

2.19

Last Year’s EPS

1.96

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 11 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 04, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call emphasized strong operational momentum across multiple businesses, robust top-line growth, successful strategic actions (PineBridge, reinsurance, PRT origination) and achievement of key 2025 targets (adjusted EPS growth, ROE, expense efficiency, and free cash flow progress). Primary near-term concerns include a modest shortfall in variable investment income (and slightly lower-than-expected private equity/real estate returns), an anticipated 2026 drag from corporate & other, a temporary rise in the direct expense ratio due to the PineBridge acquisition, and some line-specific underwriting pressure (disability). Taken together, the positives — including record PRT origination, strong regional sales, AUM growth, capital returns, and adherence to strategic commitments — materially outweigh the headwinds described, supporting a constructive outlook.

Company Guidance

The company’s near-term guidance reinforces its New Frontier commitments: management expects double‑digit adjusted EPS growth in 2026, adjusted ROE of 15%–17%, and to maintain a two‑year average free cash flow ratio of 65%–75% (supporting a five‑year free cash flow target of $25 billion, of which $4.9 billion was generated in 2025); 2026 targets include a direct expense ratio ~12.1% (PineBridge adds ~50 bps) with a 2029 target of 11.3%, favorable investment income of roughly $1.6 billion pretax, a corporate & other after‑tax loss of $500–700 million, and an effective tax rate of 24%–26% while share repurchases in 2026 are expected to be in line with 2025. Segment and product guidance includes Group Benefits PFO growth of 4%–7%, a revised group life mortality target of 83%–88% and nonmedical health interest adjusted benefit ratio of 70%–75% with Group Benefits adjusted earnings up 7%–9% in 2026; RIS retained liabilities are expected to grow 3%–5% with RIS adjusted earnings of $1.6–1.8 billion and GA spreads of 100–120 bps; Asia sales and AUM to grow mid‑single to mid‑high single digits with Asia earnings mid‑single digits; Latin America PFOs high‑single digits and adjusted earnings +6%–8% in 2026 (including ~ $50 million Mexico VAT impact); EMEA PFOs high‑single digits and a new quarterly run rate of $90–100 million in 2026; and MIM revenue growth ~30% in 2026 with MIM adjusted earnings $240–280 million (then +15%–20% p.a. in 2027–28, targeting ~32% operating margin by 2028). Additional numeric context: total VII assets ≈ $19 billion, VII return assumptions PE 9% and real estate/other 7%, year‑end MIM AUM $742 billion, holdco cash ~$3.6 billion within a $3–4 billion buffer, and US statutory NAIC RBC expected above 360%.

Strong Quarterly Adjusted EPS Performance

Q4 adjusted earnings of $1.6B (reported $2.49/sh); excluding notable items Q4 adjusted EPS was $2.58/sh, up 24% YoY (from $2.08) and described as MetLife's highest single EPS quarter.

Full-Year Financial Targets Achieved

FY 2025 adjusted earnings (ex-notables) of ~$6.0B or $8.89/sh, up roughly 10% YoY; adjusted ROE of 16% (within 15%-17% target); two-year average free cash flow ratio of 81% (above 65%-75% target); direct expense ratio improved to 11.7%, ahead of multi-year goal.

Revenue and PRT Origination Growth

Adjusted premiums, fees and other revenues (PFOs) rose 8% to $12.8B in Q4 and rose 29% to $18.6B when retained pension risk transfer (PRT) deals included; pension risk transfer originations exceeded $14B in 2025 (MetLife's highest annual PRT total).

MetLife Investment Management (MIM) Expansion and AUM Gain

Closed PineBridge acquisition and launched MIM as a segment; year-end MIM assets under management of $742B, up from roughly $600B a year ago (~+23–24%), supporting a strategic push into asset management and expected MIM revenue growth (~+30% in 2026).

Strong International Sales Momentum — Asia & Latin America

Asia constant-currency sales +18% in 2025 (Japan and Korea contributions); Asia general account AUM +7% CC; Latin America constant-currency sales +12% and Latin America adjusted PFOs +25% CC, with LATAM Q4 adjusted earnings +13%.

Capital Deployment and Shareholder Returns

Deployed ~ $4B to support organic new business in 2025; returned ~ $2.9B via share repurchases and $1.5B in dividends (total ~$4.4B); additional $200M repurchased in January; holding company cash and cash equivalents $3.6B (within $3B–$4B target).

Record Origination and Strategic Reinsurance

RIS delivered record sales of $42B in 2025, including >$14B PRT and ~ $11B UK longevity transactions (with $7B in Q4); executed strategic reinsurance transactions including two Chariot deals (~$11B liabilities) and a Talcott risk transfer (~$10B liabilities).

Expense Efficiency and Technology Adoption

Direct expense ratio fell to 11.7% for 2025, aided by AI and process reengineering — progress described as well ahead of the five-year 100-basis-point improvement target toward an 11.3% goal.

Metlife (MET) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MET Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2026	2026 (Q1)	2.19 / -	1.96	―	―	―
Feb 04, 2026	2025 (Q4)	2.34 / 2.49	2.09	19.14% (+0.40)
Nov 05, 2025	2025 (Q3)	2.32 / 2.34	1.95	20.00% (+0.39)
Aug 06, 2025	2025 (Q2)	2.15 / 2.02	2.28	-11.40% (-0.26)
Apr 30, 2025	2025 (Q1)	2.00 / 1.96	1.83	7.10% (+0.13)
Feb 05, 2025	2024 (Q4)	2.11 / 2.09	1.83	14.21% (+0.26)
Oct 30, 2024	2024 (Q3)	2.17 / 1.95	1.97	-1.02% (-0.02)
Jul 31, 2024	2024 (Q2)	2.10 / 2.28	1.94	17.53% (+0.34)
May 01, 2024	2024 (Q1)	1.84 / 1.83	1.52	20.39% (+0.31)
Jan 31, 2024	2023 (Q4)	1.88 / 1.83	1.55	18.06% (+0.28)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MET Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 04, 2026	$78.01	$75.32	-3.45%
Nov 05, 2025	$78.12	$75.43	-3.44%
Aug 06, 2025	$74.87	$72.77	-2.80%
Apr 30, 2025	$73.19	$73.58	+0.53%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Metlife (MET) report earnings?

Metlife (MET) is schdueled to report earning on May 06, 2026, After Close (Confirmed).

What is Metlife (MET) earnings time?

Metlife (MET) earnings time is at May 06, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MET EPS forecast?

MET EPS forecast for the fiscal quarter 2026 (Q1) is 2.19.

Metlife (MET) Earnings News

MetLife (NYSE:MET) Posts Gloomy Q4 Results

Premium

Market News

MetLife (NYSE:MET) Posts Gloomy Q4 Results

3y ago

MET

See More MET News >